Achilles Therapeutics PLC (ACHL)
0.902
0.00 (0.00%)
USD |
NASDAQ |
Jun 14, 16:00
0.8812
-0.02
(-2.31%)
After-Hours: 20:00
Achilles Therapeutics Enterprise Value: -73.80M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | -73.80M |
| June 13, 2024 | -73.59M |
| June 12, 2024 | -73.57M |
| June 11, 2024 | -73.99M |
| June 10, 2024 | -74.53M |
| June 07, 2024 | -73.80M |
| June 06, 2024 | -73.88M |
| June 05, 2024 | -72.20M |
| June 04, 2024 | -73.89M |
| June 03, 2024 | -73.89M |
| May 31, 2024 | -73.03M |
| May 30, 2024 | -72.19M |
| May 29, 2024 | -73.88M |
| May 28, 2024 | -73.03M |
| May 24, 2024 | -73.46M |
| May 23, 2024 | -74.05M |
| May 22, 2024 | -73.89M |
| May 21, 2024 | -72.02M |
| May 20, 2024 | -72.61M |
| May 17, 2024 | -71.85M |
| May 16, 2024 | -73.24M |
| May 15, 2024 | -73.03M |
| May 14, 2024 | -73.03M |
| May 13, 2024 | -74.32M |
| May 10, 2024 | -72.18M |
| Date | Value |
|---|---|
| May 09, 2024 | -73.09M |
| May 08, 2024 | -73.08M |
| May 07, 2024 | -77.05M |
| May 06, 2024 | -76.89M |
| May 03, 2024 | -78.00M |
| May 02, 2024 | -79.01M |
| May 01, 2024 | -78.94M |
| April 30, 2024 | -80.29M |
| April 29, 2024 | -79.87M |
| April 26, 2024 | -79.87M |
| April 25, 2024 | -79.25M |
| April 24, 2024 | -78.85M |
| April 23, 2024 | -78.97M |
| April 22, 2024 | -78.59M |
| April 19, 2024 | -78.89M |
| April 18, 2024 | -78.16M |
| April 17, 2024 | -77.54M |
| April 16, 2024 | -78.06M |
| April 15, 2024 | -77.19M |
| April 12, 2024 | -76.02M |
| April 11, 2024 | -76.02M |
| April 10, 2024 | -77.32M |
| April 09, 2024 | -76.66M |
| April 08, 2024 | -76.86M |
| April 05, 2024 | -76.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-157.05M
Minimum
May 09 2022
566.38M
Maximum
Apr 06 2021
-56.53M
Average
-100.88M
Median
Oct 31 2022
Enterprise Value Benchmarks
| Barinthus Biotherapeutics PLC | -58.36M |
| TC BioPharm (Holdings) PLC | 3.904M |
| Adaptimmune Therapeutics PLC | 114.47M |
| Biodexa Pharmaceuticals Plc | 1.287M |
| Verona Pharma PLC | 1.021B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.27M |
| Total Expenses (Quarterly) | 14.30M |
| EPS Diluted (Quarterly) | -0.30 |
| Earnings Yield | -177.4% |